Leniolisib, a well-tolerated PI3K inhibitor recently approved by the FDA for the treatment of children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) [38,39], was tested in PAECs after knockdown of either BMPR2 or CAV1. Here, PIK3CD is linked to activated PI3K-delta syndrome.